

# MicroPort Scientific Corporation

## 2022 Interim Results

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

## **FORWARD-LOOKING STATEMENTS**

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, “anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

## **CONFIDENTIALITY**

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.



# Contents

- 1 **Company Highlights**
- 2 **Business Review**
- 3 **Financial Review**
- 4 **Outlook**
- 5 **Appendix – Financial Statements**

## 1H2022 Highlights

### Revenue

**\$405.0mn**  **10.1%YOY**



#### Orthopedics

**\$107.7mn**  **2.4%YOY**  
Non-China +10%



#### CRM

**\$104.4mn**  **7.2%YOY**



#### Endovascular

**\$70.8mn**  **26.6%YOY**



#### Cardiovascular

**\$60.7mn**  **7.2%YOY**  
Int'l revenue  **28%YOY**  
Balloon revenue  **31%YOY**



#### Neurovascular

**\$31.3mn**  **22.9%YOY**



#### Heart valve

**\$19.0mn**  **44.8%YOY**



#### Surgical devices

**\$2.4mn**  **5.4%YOY**



#### Others<sup>1</sup>






**\$8.7mn**  **236.5%YOY**

\* revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies







## Business highlights


### Cardiovascular


- Int'l revenue  **28% YOY**
- EMEA  **63%**, South America  **49%**, India JV<sup>2</sup>  **31%**
- Balloon revenue  **31% YOY**





### CRM

- Int'l revenue  **8% YOY** (US  **52%**, Japan  **41%**, EMEA  **5%**)
- **1st** MRI-compatible China-made pacemaker approved & commercialized


**Heart valve:** revenue  **45% YOY**; GPM **+9** pts

**EP<sup>3</sup>:** revenue  **35% YOY** with profitability; **SSE STAR** listing (Aug-22)

**Endovascular:** revenue  **27% YOY**; rapid revenue & profit growth for 6 consecutive years

**Neurovascular:** revenue  **23% YOY**; soaring int'l revenue (US, EU, South America, APAC); **HKE** listing (Jul-22)

**Surgical robots:** First bidding order at hospital level for **Toumai®**; newly established **10+** training centers nationwide & trained **200+** physicians

**Orthopedics:** non-China  **10% YOY**; spine & trauma  **35% YOY**




## R&D achievements

**14** NMPA<sup>4</sup>, **5** CE & **5** FDA newly obtained

**26** NMPA Green Path products - **No.1** in industry for **7** consecutive years

- **Cardiovascular:** Firehawk® clinical trials (for FDA assessment) proceed as planned
- **CRM:** MRI-compatible ICD/CRT-D & Invicta™ leads **CE** marked
- **Heart Valve:** **world's first** dry-tissue TMVR system entering clinical phase
- **Endovascular:** Fishhawk™ launched clinical trails & submitted for **NMPA** Green Path
- **Neurovascular:** 4 **NMPA** approvals; Tigertriever®13 **FDA** cleared
- **Surgical robots:** Toumai® obtained **NMPA** & Toumai® II submitted for **NMPA**; Honghu (SkyWalker™) obtained **NMPA** & **FDA**







## China

**14** NMPA<sup>1</sup> newly obtained  
**26** Green Path products - **No.1** in industry for **7** years



### Cardio-vascular

- **Firehawk® Pro** obtained **NMPA**
- Anchor balloon submitted for **NMPA**; coronary rapamycin DCB & rotational atherectomy catheter launched clinical trials



### Ortho-pedics

- **3** products obtained **NMPA**, incl. Medial-Pivot knee system & total knee prosthesis
- **6** products submitted for **NMPA**, incl. zirconium niobium alloy femoral head



### CRM

- **Rega®** pacemaker (MRI OOC) & **BeFlex™** lead obtained **NMPA**
- **Kora™ 250** pacemaker (MRI) submitted for **NMPA** (Aug-22)
- **BonaFire™** passive pacing lead completed registrational clinical trials



### Endo-vascular

- **Talos®** Thoracic Stent Graft obtained **NMPA**
- Iliac venous stent completed all patients enrollment; Fishhawk™ Mechanical Thrombectomy Catheter launched clinical trials & submitted for **NMPA Green Path**



### Neuro-vascular

- **4 NMPA**: **NUMEN Silk®** Coil, **Neurohawk®** Stent Thrombectomy Device, **Diveer™** Intracranial Balloon Dilatation Catheter, **X-track™** Intracranial Distal Access Catheter
- **Tigertriever®** Revascularization Device submitted for **NMPA**



### Heart valve

- Self-developed **TMVR system** launched FIM
- **VitaFlow®**'s 5-year follow-up study proved safety and efficacy for long-term use



### Surgical robot

- **Toumai®** obtained **NMPA**; **Toumai® II** submitted for **NMPA**
- **Honghu** (TKA) obtained **NMPA**; completed **FIM** surgery for THA
- Trans-bronchial Surgical Robot launched **FIM**



### Surgical devices

- **VitaSprings™** Membrane Oxygenator submitted for **NMPA**
- Self-developed **ECMO** under type testing



### Urinary, gynecological, digestive & respiratory

- Single-use flexible digital ureteroscope catheter & single-use hemostatic clip device approved in **china**
- Prostatic urethral lift system admitted in **NMPA Green Path** & completed **FIM**



### Electro-physiology<sup>2</sup>

- Contact force-sensing catheter & high density mapping catheter submitted for **NMPA**



### Sports medicine<sup>2</sup>

- **Archimedes®** long-term implantable rotator cuff spacer system's clinical trial close to finishing; **3** products incl. 4K high-resolution arthroscope system submitted for **NMPA**



## Non-China

**5** FDA & **5** CE  
newly obtained



### Cardio-vascular

- **Firehawk®** & **Firehawk Liberty™** received **4** new registration approvals; balloon products received **7** new registration approvals
- **Firehawk®** TARGET series clinical trials (for FDA assessment) proceed well



### Ortho-pedics

- **Procotyl P Cup** launched testing for **FDA** (510k) assessment
- Hinged knee joint system & classic Profemur® Cemented XM® Femoral Stem submitted for **FDA** (510k)



### CRM

- **MRI compatible** ICDs/CRT-Ds and leads obtained **CE**, incl. **Ulys™** /**Edis™** ICD, **Gali™** CRT-D, **Invicta™** leads
- Bluetooth® pacemakers approved in **Australia**



### Endo-vascular

- **Hyperflex®** Balloon Catheter approved in **Japan**
- **Reewarm®** PTX DCB approved in **Brazil**
- **Castor®** approved for customized distribution in **EU**(Jul-22)



### Neuro-vascular

- **NUMEN®** Coil Embolization System approved in **Korea & Japan**
- **Tigertriever® 13\*** Revascularization Device obtained **FDA**



### Heart valve

- **VitaFlow Liberty™**: continued **CE** marking progress under MDR regulations; approved in **Columbia**



### Surgical robot

- **Honghu** obtained **FDA** & submitted for **CE**



### Surgical devices

- **Hemovent WATCHA** blood oxygen saturation monitoring sensor obtained **CE**



### Urinary, gynecological, digestive & respiratory

- **5** products approved in **Brazil & Thailand**
- **2** products submitted for **CE**



### Electro-physiology<sup>2</sup>

- **3 FDA**: **PathBuilder™** steerable introducer, intracardiac guide sheath & atrial septal puncture needle



### Sports medicine<sup>2</sup>

- **Archimedes®** accomplished **FDA** pre-submission



# Contents


- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix – Financial Statements



## Business highlights

### Revenue Overview

USD: million



**#1 China**  
**#2 Global**  
Market share



China

- 1H22 revenue **\$51mn**, down 11.7% YOY due to pandemic
- Guaranteed DES volume highly increased in 2<sup>nd</sup>-year renewal of VBP for Firebird2<sup>®</sup> & Firekingfisher<sup>™</sup>
- DES products covered **3,000+** hospitals; balloon products covered **~1,400** hospitals



Non-China


- 1H22 revenue **\$10mn**, up **28%** YOY (EMEA **+63%**, South America **+49%**)
- Indian JV **↑31%** for our own brands after Firehawk IN<sup>™</sup> launched
- DES received **4** new registration approvals; balloon products received **7** new registration approvals



R&D


- Firehawk<sup>®</sup>** large-scale trials for **FDA** assessment proceed well
- Firesorb<sup>®</sup>** released FUTURE-II 2-year follow-up results, showing great efficacy & safety; under FUTURE-III 1-year clinical follow-up
- Firehawk<sup>®</sup> Pro obtained **NMPA**; anchor balloon submitted application for **NMPA** review
- Coronary rapamycin **DCB** & **1<sup>st</sup>** Chinese-developed coronary rotational atherectomy catheter both launched clinical trials
- Intravascular lithotripsy balloon** at type fixing stage

## Product pipeline





## Non-China business




### Business highlights

- 1H22 revenue **\$99.7mn**, up **10%** YOY (EMEA +32%, US +3%)
- Gross profit margin continued to grow through improving sales mix, specifically for knee products
- With great success in EU, **Procotyl P Cup** launched testing for **FDA** (510k) assessment, planning to expand towards global use
- Hinge knee joint system & classic Profemur® Cemented XM® Femoral Stem launched testing for **FDA** (510k)
- Cooperated with various partners for development of surgical imaging and planning

### Cost savings

- Achieved **~\$5mn cost savings** through continued focus on expense management, incl. cross-border manufacturing collaboration and streamlining of operation teams
- Transferred partial manufacturing process to China to leverage global capabilities, partially offset the inflationary impacts

## China business




### Joints

- 1H22 revenue **\$8.0mn**, down 44%; mainly impacted by VBP & Covid in China
- Implantations of China-made joints increased by **>20%** YOY after VBP
- Newly Penetrated **>140** hospitals with total coverage of **1,500+** hospitals
- Three NMPA** approvals: new generation of China-made medial-pivot knee system, total knee prosthesis & joint guides
- Six** products submitted for **NMPA** review, incl. zirconium niobium alloy femoral head (NMPA Green Path) & VenusOne Eco Bio-acetabular System

### Spine & Trauma


- 1H22 revenue **\$3.4mn**, up **35% YOY**
- Covering **~500** hospitals in total, newly entered **~200** hospitals
- Three **NMPA** approvals: spinal plate fixation system kit, vertebroplasty tools & non-locked metal hollow bone screws
- Takin spinal posterior fixation system & arbores balloon dilatation system newly launched to market in **Argentina**
- Trauma products have submitted registration application in **Colombia**

## Non-China business



- 1H22 revenue **\$98.9mn**, up **8%** YOY
- Substantial sales growth in major markets: EMEA (our no. 1 market) **+5%**, Japan **+41%**, US **+52%**
- The strongest revenue growth was achieved with pacemakers, driven by launch of Bluetooth® pacemakers in **EU & Japan**, which were also approved in **Australia**
- Invicta™ ICD lead (MRI) certified by **CE** (Jul-22), enabling **1.5T/3T MRI compatible** systems for our ICD & CRT-D portfolio

### Product pipeline




Products newly approved for marketing



Note: 1. change of NMPA certificate; 2. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies; 2. R&D progresses until the end of Aug-22


## China business



**Top 1**  
Chinese player  
**No. 1**  
market share for  
China-made products

- 1H22 revenue **\$5.5mn**, down 7% YOY, mainly impacted by Covid
- Thanks to multiple brands of pacemakers winning bids in provincial/provincial-league VBP, products newly penetrated **~100** hospitals, covering **1,000+** in total
- First** China-made MRI compatible pacemaker Rega® obtained **NMPA**<sup>1</sup> & completed clinical implantations
- BeFlex™ pacing lead (MRI) obtained **NMPA**<sup>1</sup>; Kora™ 250 pacemaker (MRI) submitted for **NMPA** (Aug-22); BonaFire™ passive pacing lead completed clinical trails

### Product pipeline




## Business highlights

### Key Financials

USD: million

■ 1H21  
■ 1H22





### China

- 1H22 revenue \$71mn, **up 27%** YOY, driven by robust sales growth of multiple innovative products despite Covid in China
- Castor®, the world's 1<sup>st</sup> thoracic branch stent-graft system, covered **750+** hospitals, completed implantations of **12,000+** since its launch
- Minos® & Reewarm® PTX DCB have both covered **500+** hospitals respectively
- Two newly-launched products, Talos® Thoracic Stent Graft System & Fontus® Branched Surgical Stent Graft System, successfully commercialized and realized continuous implantations; both included in the procurement list of 10 provinces (by end of Jul-22)

### Global

- Products already covered **21** overseas markets across **EU**, **South America** and **Asia**, commercialized in multiple EU countries such as Germany and Portugal
- Hercules® Low Profile commercialized in **India**; Hyperflex® Balloon Catheter approved in **Japan**, becoming the 1<sup>st</sup> product entering Japanese market for this segment
- Reewarm® PTX DCB newly approved in **Brazil**; Castor® approved for customized distribution in **EU**(Jul-22)

## Product pipeline

	Product	Pre-clinical	Clinical	Registration
Aortics Stents	Talos® Thoracic Stent Graft System 	✓ <b>NMPA approved</b>		
	Cratos® Branched Aortics Stent Graft System	• In preparation for clinical trials		
	Aegis® II Abdominal Aortic Stent Graft System	• In preparation for clinical trials		
Peripheral Products	Iliac Venous Stent System 	• Completed all patients enrollment		
	Fishhawk™ Mechanical Thrombectomy Catheter	• Launched clinical trials • <b>Submitted NMPA Green Path application</b>		
	Vena Cava Filter	• Completed type testing		
Oncological	TIPS Stent Graft System	• Completed type testing		


 Product admitted to NMPA Green Path





MicroPort  
微创脑科学  
2172.HK

- Successfully listed on HKEx on July 15, 2022
- Becoming the 4<sup>th</sup> subsidiary to accomplish public listing



## China

- Newly penetrated ~250 hospitals, covering ~2,400 in total, including all top 100 hospitals in this field
- Coil provincial-VBPs: market share increased in Hebei; won bid in Jiangsu & Fujian
- Tubridge®, NUMEN®, Bridge® & U-track™ gained fast-growing market share since their launch in recent years
- Eagle & Swallows program covered ~130 lower-tier cities and counties

## Global

- International business generated a revenue of \$1.8mn (zero for 1H21)
- NUMEN® completed multiple commercial implantations in Korea, US and EU; APOLLO™ commercialized in Brazil
- Established local sales team in US, UK, South America, Japan & Australia
- Fully leverage on the global sales network and complementary product portfolio of Rapid Medical (our associated company)




Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies; 2. R&D progresses until the end of Aug-22

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	NUMEN Silk™ 3D Electronically Detachable Coil	✓ NMPA approved		
	Comaneci® Embolization Assist Device*	• CE marked & FDA cleared • FDA Breakthrough Device Designation		
	Rebridge® Intracranial Visualized Stent	• First patient enrolled in Jan-22		
Cerebral Atherosclerotic Stenosis	Diveer™ Intracranial Balloon Dilatation Catheter	✓ NMPA approved		
	Intracranial Drug-Coated Balloon Catheter System	• Design development		
	Neurohawk® Stent Thrombectomy Device	✓ NMPA approved		
Acute Ischemic Stroke	Tigertriever® 13 Revascularization Device*	✓ FDA cleared • World's smallest clot retriever		
	Tigertriever® Revascularization Device*	• CE marked & FDA cleared • Submitted for NMPA review • NMPA approval expected in 4Q22		
	Balloon Guide Catheter	• Design validation • NMPA submission expected in 2H22		
Access Product	X-track™ Intracranial Distal Access Catheter	✓ NMPA approved		
	W-track® Intracranial Aspiration Catheter	• Design validation • NMPA submission expected in 2H22		

Product admitted to NMPA Green Path \* Products we act as exclusive distributor for Rapid Medical

## Business highlights



### China

- Revenue up **45%** YOY with implantations up **60%** YOY (**1,300+** procedures)
- TAVI** newly penetrated **80+** hospitals, covering **390+** hospitals, with leading market share in **230+** hospitals
- Updates in the integrated total-solution promotion program: larger sales teams from Heart Valve & Cardiovascular business, enhanced discovery and referral schemes and full-process health management support, etc.

### Globalization

- VitaFlow Liberty™: continued **CE** marking progress under MDR regulations
- Alwide® Plus: submitted application for **CE**
- Continuous sales and implantations in **Argentina**
- VitaFlow Liberty™ & Angelguide® newly approved in **Columbia**

### R&D progress

- Self-developed TMVR system successfully launched clinical trials (FIM), becoming the **world's first dry-tissue** TMVR system entering clinical phase
- VitaFlow®**'s five-year follow-up clinical results showed great safety & efficacy
- AltaValve completed **10+** transseptal cases – **the only known** TMVR device that offers full implant retrievability even after its complete deployment and prior to its detachment from TS delivery system

## Product pipeline

	Product	Pre-clinical	Clinical	Registration
TAVI (aortic valve)	VitaFlow Liberty™	• CE marking in progress		
	VitaFlow™ III	• Design fixing stage		
	VitaFlow™ Novo Generation	• Design stage		
	VitaFlow™ Balloon Expandable	• Design stage		
	Self-developed replacement product	• <b>Successful FIM application in Jul-22</b>		
TMV (mitral valve)	AltaValve - replacement product	• <b>Early feasibility studies</b>		
	Helios - replacement product	• Animal studies		
	Self-developed edge to edge repair product	• Design fixing stage		
	Amend™ - repair product	• <b>Early feasibility studies</b>		
	Self-developed edge to edge repair product	• Design stage		
TTV (tricuspid valve)	Trivid - repair product	• Animal studies		
	Replacement product - partnership with 4C	• Design stage		
	Aortic valve replacement product	• Design stage		
Surgical	Mitral valve replacement product	• Design fixing stage		
	VitaGuardian™ Embolic Protection Device	• <b>Submitted NMPA Green Path</b>		
Procedural Accessories	Expandable Sheath	• Design stage		

## Business highlights

### Market development

- Obtained first bidding order at hospital level for **Toumai®**
- Deployed **~30** training centers, incl. self-owned and co-developed with hospitals
- Trained **200+** doctors; completed **~800** training operations
- **World's 1st** 5G remote surgery training center

### R&D progress

#### Laparoscopic surgery

- **Toumai®1<sup>st</sup> Generation** obtained **NMPA**
- **Toumai®2<sup>nd</sup> Generation** completed registrational clinical trial in gynecologic, thoracic & general surgeries
- **Toumai®** completed **world's longest-distance 5G** ultra-remote surgery
- **Toumai® single-arm** completed research clinical trials

#### Orthopedic surgery

- Honghu<sup>1</sup> (TKA) obtained **NMPA & FDA**; submitted for **CE**
- Honghu (THA) completed **FIM** surgery (Aug-22)

#### Natural orifice surgery

- Trans-bronchial Surgical Robot completed **FIM** clinical trial

#### Panvascular surgery

- **R-ONE®** completed enrollment of registrational clinical trial

#### Percutaneous surgery

- **Mona Lisa™** completed registrational clinical trial; submitted for **NMPA**

### Globalization

- **Honghu** obtained **FDA (510k) clearance**, becoming **1st FDA-cleared** Chinese-developed surgical robot
- Establishing a **professional commercial team**; trained surgeons from **four hospitals** in US

### Product

### Pre-clinical

### Clinical

### Registration

#### Laparoscopic

Toumai® Laparoscopic Surgical Robot ("Toumai®")



✓ **Obtained NMPA**

Toumai® 2<sup>nd</sup> Generation



• Completed multi-disciplinary clinical trials

Toumai® Single-arm Laparoscopic Surgical Robot

• Completed FIM clinical trial

#### Orthopedic

Honghu (Skywalker™) Orthopedic Surgical Robot



✓ **Obtained NMPA & FDA (510k)**



Spine Surgical Robot

• Design validation stage

#### Natural Orifice

Trans-bronchial Surgical Robot

• Completed FIM clinical trial

#### Panvascular

R-ONE® Vascular Interventional Surgical Robot



• Completed clinical trial enrollment in China  
• Obtained **CE** in 2019



TAVR Surgical Robot

• Design development stage

#### Percutaneous

iSR'obot™ Mona Lisa Robotic Transperineal Prostate Biopsy System ("Mona Lisa")



• Submitted for **NMPA** review  
• Obtained **CE & FDA** in 2017



Thoracic and Abdominal Puncture Robot

• Design validation stage





## Urinary, gynecological, digestive & respiratory

- Provide innovative total solutions in endoscope and disposal devices to **urological, gastrointestinal, gynecological & respiratory** diseases
- **16** registration certificates in total
- Single-use flexible digital ureteroscope catheter & single-use hemostatic clip device approved in **china**; prostatic urethral lift system admitted in **NMPA Green Path** & completed **FIM**
- **5** products approved in **Brazil** and **Thailand**, **2** products at **CE** registration stage, marking debut in international market



## Pharmaceuticals (API)

- Engaged in **characteristic microbial fermentation APIs** incl. rapamycin, cyclosporine, tacrolimus and mycophenolate mofetil, with sales scope already covering **US, Japan & EU**
- **19-21 CAGR** of revenue & profit both reached **~50%**




## Medical imaging

- Provide **total precise interventional imaging** solution
- **OCT** successfully commercialized, achieving a rapid market introduction by leveraging on our existing channel resources
- New generation OCT (high-speed) under registration in China
- **IVUS** completed preliminary animal study



## Ophthalmology, ENT & dental

- **Ophthalmology: Ortho-k lenses** completed type validation
- **ENT:** provide solutions incl. sinus drug delivery & artificial hearing repair
- **Dental:** artificial tooth implant and orthodontic solutions under R&D



# Contents


- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix – Financial Statements





## Revenue

USD: million




## Gross profit margin




## Operating expenses

USD: million




## Total net loss & net loss attributable to equity shareholders

USD: million



## Sales & marketing expenses

USD: million




**Sales & marketing expenses increased by 12.2%<sup>YOY</sup>**

- ◆ Increase in marketing activities and product promotion

## Administrative expenses

USD: million




**Administrative expenses increased by 29.4%<sup>YOY</sup>**

- ◆ Increase in the cost related to new office premises and facilities
- ◆ Additional administrative expenses of subsidiaries newly acquired in the second half of 2021

## R&D expenses

USD: million




**R&D expenses increased by 59.3%<sup>YOY</sup>**

- ◆ Due to increased investments in R&D projects

# Net loss analysis by segment

USD: million





# Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix – Financial Statements



# Innovative product pipeline fueling long-term growth

Cardio-vascular	Firefighter™ Pro/NC Pro NMPA	Anchor Balloon NMPA	Firesorb® Bioresorbable Scaffolds NMPA&CE		Firehawk® FDA	Coronary Stent Graft System NMPA	Coronary Rotational Atherectomy System NMPA&CE		Intravascular Lithotripsy Balloon NMPA&CE		Coronary Rapamycin Drug-coated Balloon (DCB) NMPA	
Orthopedics	VenusOne ECO Bio-acetabular System NMPA		Classic Profemur® Cemented XM® Femoral Stem FDA	Zirconium Niobium Alloy Femoral Head NMPA		Hinged Knee Joint System FDA		2D-to-3D Imaging Technology FDA		Wrist Joint Prosthesis System NMPA		
CRM	Kora™ 250 Pacemaker (MRI) NMPA		Bluetooth® ICD & CRT-D CE		ENO™ Pacemaker & BonaFire™ Passive Lead (MRI) NMPA		Space HP ICD/CRT-D NMPA		Invicta™ ICD Lead & Navigo™ CRT Lead (MRI) NMPA		Leadless Pacemaker NMPA&CE	
Endo-vascular	Iliac Venous Stent System NMPA		Fishhawk™ Mechanical Thrombectomy Catheter NMPA	Vena Cava Filter NMPA		Cratos Branched Aortics Stent Graft System NMPA		Aegis® II Abdominal Aortic Stent Graft System NMPA		TIPS Stent Graft System NMPA		
Neuro-vascular	Tigertriever™ Revascularization Device NMPA	X-track™ Intracranial Distal Access Catheter NMPA		Comaneci® Embolization Assist Device NMPA		Rebridge® Intracranial Visualized Stent NMPA		Tubridge Plus™ Flow-diverting Stent NMPA		Balloon Protection Guiding Catheter NMPA		
Heart Valve	VitaFlow® III NMPA	VitaFlow™ Novo Generation NMPA	VitaFlow® Balloon Expandable NMPA	Mitral Replacement: Self-developed replacement product AltaValve™ Helios™			Mitral Repair: Self-developed edge to edge repair product Amend™			Tricuspid Repair: Self-developed edge to edge repair product Trivid		Embololic Protection Device NMPA
Surgical Robot	Toumai® 2nd Gen Laparoscopic Surgical Robot NMPA		Toumai® Single-arm Laparoscopic Surgical Robot NMPA	R-ONE® Panvascular Surgical Robot NMPA			iSR'obot™ Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA			Trans-bronchial Surgical Robot NMPA	TAVR Surgical Robot NMPA	Spine Surgical Robot NMPA
Surgical Devices	VitaSprings™ Membrane Oxygenator NMPA		Femoral Arterial & Venous Cannula NMPA	Arterial Micro-Embollic Filter (new type) NMPA		ECMO NMPA			MOBYBOX System NMPA			
Electro-physiology <sup>1</sup>	High Density Mapping Catheter NMPA		Contact Force-Sensing Catheter NMPA	Cryoablation Catheter NMPA			IceMagic® Cardiac Cryoablation System NMPA			Renal RF Ablation System NMPA		Flashpoint® Renal Artery Ablation Catheter NMPA



# Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix – Financial Statements





USD'000	2022 1H	2021 1H	Var.
Revenue	404,984	384,611	5.3%
Cost of sales	(157,282)	(137,003)	14.8%
<b>Gross profit</b>	<b>247,702</b>	<b>247,608</b>	<b>0.0%</b>
Other net income	41,356	24,622	68.0%
Research and development costs	(186,430)	(117,064)	59.3%
Distribution cost	(146,610)	(130,689)	12.2%
Administrative expenses	(133,259)	(102,987)	29.4%
Other operating costs	(8,328)	(5,466)	52.4%
<b>Loss from operations</b>	<b>(185,569)</b>	<b>(83,976)</b>	<b>121.0%</b>
Finance cost	(46,050)	(21,905)	110.2%
Gain on deemed disposal of a subsidiary	-	8,219	N/A
Gain on deemed disposal of interest in equity-accounted investees	1,920	523	267.1%
Share of losses of equity-accounted investees	(18,141)	(5,255)	245.2%
<b>Loss before taxation</b>	<b>(247,840)</b>	<b>(102,394)</b>	<b>142.0%</b>
Income tax	(5,435)	(12,282)	-55.7%
<b>Loss for the period</b>	<b>(253,275)</b>	<b>(114,676)</b>	<b>120.9%</b>
<b>Attributable to: Equity shareholders of the Company</b>	<b>(198,130)</b>	<b>(90,266)</b>	<b>119.5%</b>

USD'000	30 June 2022	31 Dec 2021	Var.
<b>Non-current assets</b>			
Investment properties	7,003	7,407	-5%
Other property, plant and equipment	921,380	922,874	0%
Intangible assets	238,458	256,609	-7%
Goodwill	280,194	290,565	-4%
Equity-accounted investees	406,087	363,103	12%
Other financial assets	30,711	30,184	2%
Deferred tax assets	21,305	20,368	5%
Other non-current assets	89,996	102,652	-12%
<b>Total non-current assets</b>	<b>1,995,134</b>	<b>1,993,762</b>	<b>0%</b>
<b>Current assets</b>			
Inventories	320,878	289,931	11%
Trade and other receivables	292,879	308,126	-5%
Pledged deposits and time deposits	63,221	32,890	92%
Cash and cash equivalents	1,380,798	1,754,414	-21%
Derivative financial assets	-	1,406	N/A
<b>Total current assets</b>	<b>2,057,776</b>	<b>2,386,767</b>	<b>-14%</b>
<b>Current liabilities</b>			
Trade and other payables	336,843	358,792	-6%
Contract liabilities	21,153	23,590	-10%
Lease liabilities	65,520	50,505	30%
Interest-bearing borrowings	112,890	94,746	19%
Income tax payable	16,696	19,124	-13%
Derivative financial liabilities	871	-	N/A
<b>Total current liabilities</b>	<b>553,973</b>	<b>546,757</b>	<b>1%</b>
<b>Net current assets</b>	<b>1,503,803</b>	<b>1,840,010</b>	<b>-18%</b>

USD'000	30 June 2022	31 Dec 2021	Var.
<b>Non-current liabilities</b>			
Interest-bearing borrowings	308,720	269,637	14%
Lease liabilities	137,454	168,437	-18%
Deferred income	32,885	35,098	-6%
Convertible bonds	668,380	660,369	1%
Contract liabilities	24,238	26,243	-8%
Other payables	434,361	425,914	2%
Deferred tax liabilities	24,720	27,692	-11%
Derivative financial liabilities	611	2,890	-79%
<b>Total non-current liabilities</b>	<b>1,631,369</b>	<b>1,616,280</b>	<b>1%</b>
<b>CAPITAL AND RESERVE</b>			
Share capital	18	18	-
Reserves	1,234,675	1,490,732	-17%
<b>Total equity attributable to equity shareholders of the Company</b>	<b>1,234,693</b>	<b>1,490,750</b>	<b>-17%</b>
Non-controlling interests	632,875	726,742	-13%
<b>Total equity</b>	<b>1,867,568</b>	<b>2,217,492</b>	<b>-16%</b>



This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

## **FORWARD-LOOKING STATEMENTS**

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, “anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

## **CONFIDENTIALITY**

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.